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Summary
Background Bisphosphonates might modulate the development of symptomatic bone metastases in men with prostate 
cancer. The Medical Research Council (MRC) PR05 and PR04 randomised controlled trials assessed the use of sodium 
clodronate, an oral, ﬁ rst-generation bisphosphonate. We report the ﬁ nal analyses of long-term survival data with 
additional follow-up in both trials.
Methods 311 men with metastatic disease were recruited to PR05 between 1994 and 1998, and 508 men with 
non-metastatic disease were recruited to PR04 from 1994 to 1997. All men were treated according to the recruiting 
site’s standard practice at the time: for metastatic disease, all men were starting or responding to long-term hormone 
therapy; for non-metastatic disease, most men had radiotherapy, hormone therapy, or both. Men were randomly 
assigned to take four tablets per day of sodium clodronate (2080 mg) or matching placebo for up to 3 years 
(metastatic disease) or 5 years (non-metastatic). Long-term overall survival was assessed on an intention-to-treat 
basis in all men at sites in England and Wales using data from the National Health Service Information Centre, 
which held data for 278 of 311 men in the PR05 trial and 471 of 508 men in the PR04 trial. These studies are 
registered International Standardised Randomised Controlled Trials, numbers ISRCTN38477744 (PR05) and 
ISRCTN61384873 (PR04).
Findings Of the 278 men with metastatic disease, 258 (93%) were reported to have died. Evidence of a beneﬁ t for those 
with metastatic disease from use of sodium clodronate compared with placebo was seen in overall survival (hazard 
ratio [HR] 0·77, 95% CI 0·60–0·98; p=0·032). Of the 471 men with non-metastatic disease, 281 (60%) were reported 
to have died, with no evidence of improvement in overall survival with clodronate compared with placebo (HR 1·12, 
0·89–1·42; p=0·94).
Interpretation Long-term data from these trials show that a ﬁ rst-generation bisphosphonate, sodium clodronate, 
improves overall survival in men with metastatic prostate cancer who are starting hormone therapy, but there is no 
evidence of an eﬀ ect in men with non-metastatic prostate cancer.
Funding UK MRC; and an education grant and free drug from Roche Products Ltd.
Introduction
Bisphosphonates might modulate the development of 
symptomatic bone metastases in men with prostate 
cancer. The Medical Research Council (MRC) PR051 and 
PR042 randomised controlled trials assessed the role of 
adjuvant sodium clodronate in men with metastatic (M1) 
and non-metastatic (M0) prostate cancer, respectively. 
Both trials have previously reported results on their 
primary outcome measures.1,2
Overall survival was a secondary outcome measure in 
both trials, but the overall survival data were immature 
when the primary analyses were published. The 
metastatic trial, PR05, previously showed some evidence 
of improvement in overall survival with clodronate 
(hazard ratio [HR] 0·80, 95% CI 0·62–1·03); whereas 
the non-metastatic trial, PR04, did not show evidence of 
a beneﬁ t in overall survival (HR 1·02, 95% CI 
0·80–1·30). 
Now, 5 years after the primary outcome measure of the 
metastatic trial was published, we report the long-term 
survival data. The aim of this paper is to report ﬁ nal 
analyses of long-term survival data with additional 
follow-up in both trials.
Methods
Patients
The methods for these two trials have been fully described 
previously.1,2 In summary, 311 men with bony metastases 
from prostate cancer (M1) and 508 men with prostate cancer 
with out metastases (M0) gave written informed consent to 
join these two multi centre, double-blind, placebo-controlled 
randomised controlled trials, which opened to recruit ment 
in June, 1994, and successfully completed accrual in July, 
1998, and December, 1997, respectively. All sites obtained 
ethics approval. The trial was run under a Clinical Trial 
Marketing Product licence from the regulatory authority.
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Randomisation and masking
Randomisation was done centrally using minimisation 
across a number of stratiﬁ cation factors to ensure balanced 
groups. In the PR05 trial in men with metastatic disease, 
the stratiﬁ cation factors were treatment centre, time since 
starting long-term hormone therapy (≤6 weeks vs 
>6 weeks), type of hormone therapy (monotherapy vs 
maximal androgen blockade), and WHO performance 
status. In the non-metastatic trial, PR04, the stratiﬁ cation 
factors were: treatment centre, tumour stage (T2 vs T3 vs 
T4), primary therapy (given vs not given), time from 
primary therapy to trial entry (none vs ≤12 months vs 
>12 months), and prostate-speciﬁ c antigen (PSA) concen-
tration at study entry (<50 ng/mL vs ≥50 ng/mL). Men 
were randomly assigned to supplement the usual treatment 
for their prostate cancer with four tablets each day of oral 
sodium clodronate (2080 mg), or a matching placebo. 
Procedures
Clodronate and placebo were provided free by Roche 
Products Ltd (Hertfordshire, UK), formerly Boeringher 
Mannheim (Lothian, UK). Men with metastatic disease 
were just starting or were already responding to standard 
treatment with hormone therapy (androgen suppression), 
which was maintained through out the trial period. Men 
with non-metastatic disease were treated according to local 
standard practice, which was usually with radiotherapy, 
hormone therapy, or combined therapy. Trial medication 
was taken for a maximum of 3 years in men with 
metastases and 5 years in men without metastases. The 
primary outcome measure was the progression of symp-
tom atic bone metastases or death from prostate cancer in 
the metastatic setting, or the development of symptomatic 
bone metastases or death from prostate cancer in the 
non-metastatic setting. There were no routine scans for 
asymptomatic bone metastases. After a primary outcome 
measure event, treatment was given according to standard 
practice at the site. Overall survival and toxicity were 
secondary outcome measures speciﬁ ed in the protocol. 
For this analysis, which is only assessing long-term 
overall survival, we have supplemented follow-up with data 
from the UK National Health Service Information Centre 
(NHS IC), which provides data for patients from England 
and Wales. All patients from England and Wales who were 
successfully ﬂ agged are included in the analyses: 278 (89%) 
of 311 men with metastatic disease, and 471 (93%) of 508 
men with non-metastatic disease. Patients from Scotland 
and New Zealand are not included in these analyses 
because the NHS IC does not cover these nations. Figure 1 
shows the process of ﬂ agging and the data available. 
Statistical analysis
All analyses were done at the MRC Clinical Trials Unit 
with Stata version 10 on an intent ion-to-treat basis, using 
standard survival-analysis methods—ie, comparisons with 
log-rank tests and Cox proportional hazard-regression 
models with graphical representations using Kaplan-Meier 
plots. As before, we assumed that patients not reported by 
the NHS IC as having died when the data were locked on 
Sept 29, 2008, were alive 6 weeks beforehand. Exploratory 
interaction analyses were done using either χ² tests for 
interaction or trend, as appropriate, to examine the consist-
ency of the treatment eﬀ ect in diﬀ erent subgroups; the 
degrees of freedom are speciﬁ ed in each instance. The 
subgroups used were the same as those used for previous 
analyses.1,2 CI are given at the 95% level; p values are given 
to two signiﬁ cant ﬁ gures. Since this is a planned long-term 
report of the survival data, no formal adjustment of p values 
was required. These studies are registered International 
Standardised Randomised Controlled Trials, numbers 
ISRCTN38477744 (PR05) and ISRCTN61384873 (PR04).
Role of funding source
The sponsor and main funder of the trial had no role in 
the design and conduct of the trial or in the analysis of 
the data. Roche Products Ltd were involved in the design 
of the study, but not the analysis; they were invited to 
submit comments on an early version of this manuscript. 
The corresponding author had full access to the data and 
Men with prostate cancer 
assessed for metastases 
508 men with no metastatic disease  
(M0) recruited to PR04
311 men with metastatic disease (M1) 
recruited to PR05
474 registered in England or Wales 280 registered in England or Wales
34 excluded: not registered
in England or Wales  
31 excluded: not registered
in England or Wales  
471 successfully ﬂagged with NHS IC 88 successfully ﬂagged with NHS IC
2 excluded: not successfully
ﬂagged with NHS IC 
471 patients included in long-term 
analyses 
281 deaths (60%) 
278 patients included in long-term 
analyses
258 deaths (93%) 
508 patients included in primary analyses
257 deaths (51%) 
311 patients included in primary analyses
235 deaths (76%) 
190 not ﬂagged with NHS  IC
as death already reported  
3 excluded: not successfully
ﬂagged with NHS IC 
Figure 1: Trial proﬁ le
NHS IC=NHS Information Centre (formerly Oﬃ  ce for National Statistics). This ﬁ gure shows the process of ﬂ agging 
and the data available. All patients on PR04 were ﬂ agged before the main, previously reported analyses, but 
ﬂ agging was not done in 190 patients in the PR05 trial who were already known to have died by that point. The 
NHS IC only provides information on patients who live in England and Wales. Therefore, 50 patients from Scotland 
and 15 patients from New Zealand have been excluded from these analyses. Similarly, we have excluded ﬁ ve 
patients from England and Wales who could not be matched with the NHS IC database.
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had ﬁ nal responsibility for the decision to submit the 
manuscript for publication.
Results
Over the 5-year period since the previous results, maturity 
in the metastatic trial, PR05, increased from 235 (76%) 
reported deaths in 311 men at the previously reported 
analyses to 258 (93%) deaths in 278 men here, with a 
median follow-up of 11·5 years, compared with 4·9 years 
previously. For overall survival, there is evidence that 
clodronate confers a beneﬁ t compared with placebo, with 
an HR of 0·77 (95% CI 0·60–0·98; p=0·032). The estimated 
5-year survival was 21% with placebo and 30% with 
clodronate; the estimated 10-year survival was 9% with 
placebo and 17% with clodronate (ﬁ gure 2A). In sensitivity 
analyses, adjusting the analyses for the stratiﬁ cation factors 
(ignoring centre) does not aﬀ ect the estimate of the HR 
(data not shown).
In the non-metastatic trial, PR04, the number of deaths 
increased from 257 (51%) reported deaths in 508 men in 
the previously reported analyses to 281 (60%) deaths in 
471 men here, with a median follow-up of 12·0 years, 
compared with 9·8 years previously. There is no evidence 
of a beneﬁ t to clodronate, with a HR of 1·12 (95% CI 
0·89–1·42; p=0·94). The estimated 5-year survival was 
80% with placebo and 78% with clodronate; 10-year survival 
rates were 51% with placebo and 48% with clodronate 
(ﬁ gure 2B). 
We did further exploratory interaction analyses for the 
PR05 trial in men with metastatic disease. Tests for inter-
action showed some evidence of heterogeneity in treat-
ment eﬀ ect on survival in subgroups deﬁ ned by alkaline 
phos phatase (heterogeneity χ²=4·35, df 1; p=0·037) and 
serum creatinine (heterogeneity χ²=5·16, df 1; p=0·023; 
ﬁ gure 3A), with larger treatment eﬀ ects with higher 
concentrations of alkaline phosphatase and serum 
creatinine. Tests for inter action also showed some evidence 
of an increased treatment eﬀ ect in men who had bone 
metastases for a shorter time before randomisation 
(hetero geneity χ²=3·69, df 1; p=0·055), and in men who 
had a shorter time from diagnosis to trial entry 
(heterogeneity χ²=3·61, df 1; p=0·058; ﬁ gure 3A). There 
was no evidence of heterogeneity in treatment eﬀ ect in 
subgroups deﬁ ned by WHO PS (χ²=2·74, df 1; p=0·098), 
nor was there evidence of diﬀ erent sized treatment in 
subgroups deﬁ ned by age at random isation (tertiles), 
haemoglobin (tertiles), PSA, and time from starting 
hormone therapy to randomisation (data not shown). 
In the PR04 trial of men with non-metastatic disease, 
exploratory interaction analyses focused on the choice of 
primary treatment, although the numbers are small in 
each of these groups. This analysis showed no evidence of 
an interaction of clodronate with primary therapy given as 
radio therapy, hormone therapy, or both in terms of overall 
survival (ﬁ gure 3B; heterogeneity χ²=1·13, df 2; p=0·57). 
The type of primary therapy administered is likely based 
on the underlying stage of disease. There was no evidence 
of heterogeneity of the treatment eﬀ ect of clodronate in 
patients receiving clodronate with long-term hormone 
therapy in the metastatic trial and the non-metastatic trial 
(ﬁ gure 3B; heterogeneity χ²=0·84, df 1; p=0·36).
Discussion
Overall survival remains an important long-term outcome 
measure in both metastatic and non-metastatic disease. 
It is of clear clinical relevance, and determining the 
precise cause of death can be controversial. Here, we 
report an advantage in overall survival conferred by 
clodronate in men with metastases who joined the PR05 
trial, but no evidence of a diﬀ erence in survival in men 
without metastases in the PR04 trial. 
These analyses considered only patients from England 
and Wales, which was around 90% of the patients in each 
trial. Patients from Scotland and New Zealand were not 
included in these analyses because the NHS IC does not 
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Figure 2: Overall survival by group in metastatic disease (PR05; A) and localised disease (PR04; B)
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representing the deaths during these intervals.
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cover these countries. The strengths of using NHS IC data 
are the provision of longer-term information, in which 
deaths are very unlikely to have been missed, and in which 
there is no bias in the reporting of events by centre or 
treatment. These beneﬁ ts far outweigh the limitations of 
omitting the remaining patients. The choice not to go back 
to any centres for this analysis, and to rely on only register 
data, was made before these analyses were done. There is 
no basis for us to believe that there might be heterogeneity 
of treatment eﬀ ect between the diﬀ erent countries. 
Why have these two trials given apparently contradictory 
results—is this due to biological factors related to the 
development and progression of bone metastases or just 
the play of chance? Certainly, both trials are modestly sized, 
with just over 800 patients recruited in total. The power 
calculations were based around the previously reported 
primary outcome measures rather than overall survival 
and diﬀ erences in survival might be attributable to chance, 
even though these analyses are based on 281 deaths in the 
non-metastatic setting and 258 deaths in the metastatic 
setting. The trial in men with metastatic disease has 
probably now reached its maximum feasible maturity. 
However, in the metastatic setting (PR05) we have previ-
ously reported other beneﬁ ts in terms of symptomatic-
bone-progression-free survival with an increase in time to 
deterioration of performance status (HR 0·71, 95% CI 
0·56–0·92) and biologically measured favourable eﬀ ects 
on both alkaline phosphatase and PSA nadir levels in 
favour of clodronate therapy.1 Exploratory interaction 
analyses for the metastatic trial, reported here and 
previously,1 suggest greater relative beneﬁ t with prompt 
initiation of clodronate for men with poorer prognostic 
features such as raised alkaline phosphatase and creatinine. 
Patients with raised alkaline phosphatase would be 
expected to have increased osteoblastic activity, and we 
speculate that this patient population with an increased 
disease burden might also have a greater degree of 
osteoclast activation and bone lysis, which might be 
modiﬁ ed with early bisphosphonate treatment. A raised 
creatinine level might lead to decreased bisphosphonate 
excretion, and therefore relatively greater drug exposure 
and more biological eﬀ ect.
In the trial in men with non-metastatic disease (PR04), 
exploratory interaction analyses focused on primary 
therapy, because the choice of primary therapy would 
have been a reﬂ ection of both disease stage and standard 
local practice. However, there was no evidence of an 
interaction between the eﬀ ects of primary therapy and 
clodronate. For the group treated with a combination of 
radiotherapy and androgen deprivation, which would 
now be regarded as the standard of care for men with 
intermediate and high-risk localised disease,3–5 the HR 
was 0·95 (95% CI 0·57–1·57).
The principal action of bisphosphonates is to decrease 
osteoclast activity, and therefore bone resorption. 
Additional eﬀ ects might include a secondary reduction of 
tumour-producing growth factors, inhibition of the 
adhesion of tumour cells to bone matrix, and the 
induction of tumour-cell apoptosis. They have an 
established role in the management of myeloma and 
metastatic breast cancer, and the treatment of hyper-
calcaemia related to malignancy.6,7 Prostate cancer is 
characterised by osteoblastic metastases, and it remains 
controversial as to whether osteoclast activation is a 
necessary precursor for the development of these sclerotic 
skeletal metastases, or occurs as a consequence of their 
presence.8–10 The results of our pair of trials support the 
latter hypothesis, as the beneﬁ t of clodronate seemed to 
be restricted to the progression of established metastases. 
Never theless, the more potent amino-bisphosphonates 
might also have direct eﬀ ects on tumour cells; inducing 
apop tosis and inhibiting invasion through the inhibition 
of the mevalonate pathway.11 Indeed, a recent study in 
local ised breast cancer12 suggests an improvement in 
disease-free survival in patients treated with zoledronic 
acid compared with placebo (HR 0·64, 95% CI 
0·46–0·91). 
When the trials started in the early 1990s, chemotherapy 
was not routinely used in the UK to any extent to treat 
prostate cancer, and the options for treatment after 
ﬁ rst-line hormone therapy were very limited. The events 
reported in the primary outcome, based on time to newly 
symptom atic bone metastases, might have triggered 
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PR04 (M0) HT+RT 31/68 29/64 0·95 (0·57–1·57)
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Figure 3: Exploratory subgroup analyses of the eﬀ ect of clodronate in metastatic disease (PR05; A) and in 
non-metastatic disease (PR04; B), and compared with metastatic disease where all patients received 
hormone therapy
Alk phos=alkaline phosphatase. HT=hormone therapy. RT=radiotherapy. M0=non-metastatic disease. M1=metastatic 
disease. WHO PS=World Health Organization performance status. (A) Alkaline phosphatase was dichotomised at a 
value of 200 IU/L, separating most of the values from a long tail. Serum creatinine (μmol/L) was divided into tertiles. 
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alternative additional treatments in most cases in both 
trials, and these were previously summarised for the 
metastatic trial.1 There were also very few data to suggest 
that variations in second-line or third-line hormone 
treatment would make a diﬀ erence to survival. We took 
the pragmatic decision not to collect detailed subsequent 
data on treatment until death, as we felt that this would 
be over-burdensome. There is no good reason to think 
there is an imbalance of these treatments across the trial 
groups.
In prostate cancer, trials with much more potent bisphos-
phonates such as zoledronic acid should help clarify the 
situation for men with hormone-sensitive prostate cancer 
in due course; a non-statistically signiﬁ cant trend for im-
proved survival has already been reported using zoledronic 
acid in men with castrate-resistant disease.13 In men with 
hormone-sensitive disease, ongoing randomised controlled 
trials for men with high-risk locally advanced disease 
include the European Association of Urology’s ZEUS trial 
(ISRCTN66626762) across Europe, which compares stand-
ard treatment with or without 4 mg infusions of zoledronic 
acid every 3 months for a total of 4 years. Additionally, the 
Trans-Tasman Radiation Oncology Group’s RADAR trial 
(NCT00193856) in Australia and New Zealand, which is a 
four-arm trial in men having standard radiotherapy for 
prostate cancer, is comparing the eﬀ ects on survival of 
duration of androgen suppression (given for either 5 or 
18 months) and use of zoledronic acid (not given or given 
as 4 mg every 3 months for 18 months). In men with 
hormone-therapy-naive metastatic disease, the Cancer and 
Leukemia Group B CALGB-90202 trial (NCT00079001) in 
North America compares the eﬀ ect of zoledronic acid, 
given as 4 mg injections every 4 weeks, with placebo. 
Additionally, the lead investigators from PR04 and PR05 
have been involved in the design and conduct of the 
ongoing MRC-led STAMPEDE trial (ISRCTN78818554).14,15 
STAMPEDE is a trial for men with locally advanced or 
metastatic disease, and recruits similar populations to the 
PR04 and PR05 trials. In this six-arm trial, men starting 
long-term hormone therapy for the ﬁ rst time are randomly 
assigned to supplement this treatment with 4 mg 
zoledronic acid given intravenously every 3–4 weeks for 
2 years. The other research drugs in STAMPEDE are the 
taxane chemotherapy docetaxel, which is given for six 
cycles, and the COX2 inhibitor celecoxib, which is given 
for 1 year. Patients in STAMPEDE are randomly assigned 
to receive hormone therapy alone (control group), or 
hormone therapy plus docetaxel; hormone therapy plus 
zoledronic acid; hormone therapy plus celecoxib; hormone 
therapy plus docetaxel plus zoledronic acid; or hormone 
therapy plus zoledronic acid plus celecoxib. The 2:1:1:1:1:1 
randomisation means that 43% of patients are randomised 
to receive bisphosphonate. Between 2000 and 3000 men 
will join the trial; over 1000 patients have already been 
enrolled.
In conclusion, PR05 is the ﬁ rst trial, to our knowledge, to 
show an overall survival beneﬁ t conferred by an oral 
bisphosphonate when given in addition to standard 
hormone therapy to men with bone metastases who are 
starting or responding to hormone therapy for prostate 
cancer. However, there is no evidence that clodronate is of 
any beneﬁ t when given as an adjuvant to treatment in men 
with non-metastatic prostate cancer.
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